Brasília – The National Health Surveillance Agency (ANVISA) reports that it has received at least 14 registration requests for medicines containing semaglutide, reflecting strong industry interest following the expiration of the molecule’s patent in March 2026. The agency notes that these applications are at different stages of review and are subject to standard regulatory requirements…